by Peter Ciszewski | Sep 26, 2023
Ionis Pharmaceuticals announced positive topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS). The study demonstrated a statistically significant reduction in triglyceride (TG) levels and a 100 percent...
by Peter Ciszewski | Sep 26, 2023
Telemedicine has emerged as a transformative tool in healthcare, revolutionizing the way doctors and patients interact. By leveraging technology, telemedicine allows patients to receive medical consultations and treatments remotely, eliminating the need for in-person...
by Peter Ciszewski | Sep 16, 2023
The U.S. Food and Drug Administration has approved momelotinib (Ojjaara) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults...
by Peter Ciszewski | Sep 11, 2023
Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center have proudly received the designation as a Rare Disease Center of Excellence by the National Organization for Rare Disorders (NORD). This recognition solidifies the academic medical...
by Peter Ciszewski | Sep 1, 2023
The US FDA has assigned a priority review status to dasiglucagon in addressing congenital hyperinsulinism (CHI). The aim of dasiglucagon is to prevent and treat hypoglycemia in pediatric patients 7 days and older who suffer from CHI, with the treatment lasting up to...
